市場調査レポート
商品コード
1426120
イムノアッセイの世界市場の評価:製品別、技法別、検体別、用途別、エンドユーザー別、地域別、機会、予測(2017年~2031年)Immunoassay Market Assessment, By Product, By Technique, By Specimen, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
イムノアッセイの世界市場の評価:製品別、技法別、検体別、用途別、エンドユーザー別、地域別、機会、予測(2017年~2031年) |
出版日: 2024年02月16日
発行: Market Xcel - Markets and Data
ページ情報: 英文 223 Pages
納期: 3~5営業日
|
世界のイムノアッセイの市場規模は、2023年の341億1,000万米ドルから2031年に496億3,000万米ドルに達し、予測期間の2024年~2031年にCAGRで4.8%の成長が見込まれています。世界のイムノアッセイ市場の成長は、慢性疾患や感染症の流行、老年人口の増加、バイオテクノロジー産業の技術の進歩やイノベーション、医療支出の増加、政府の取り組みなどのさまざまな要因によってもたらされます。
世界のイムノアッセイ市場は、心血管疾患、糖尿病、がんなどの慢性疾患の有病率が世界中で高まっていることから、力強い成長を示しています。座りがちなライフスタイル、不健康な食事、アルコールやタバコの消費の増加が、慢性疾患患者数の増加の主な危険因子となっています。また、感染症の増加も、市場成長を加速させています。イムノアッセイは、複数の疾患の検出とモニタリングにおいて重要な役割を担っているからです。老年人口の増加は、慢性疾患だけでなく感染症のもっとも一般的な危険因子の1つです。イムノアッセイは、スクリーニングや定期的なモニタリングの観点から、これらの疾患を正確かつ迅速に診断するのに用いる重要なツールです。質の高い医療を提供し、医療施設をアップグレードするため、政府はより効果的で効率的なイムノアッセイプラットフォームや技術の研究開発(R&D)に投資するよう民間企業に奨励しています。さらに、病院、診療所、バイオテクノロジー企業などのさまざまな医療部門でイムノアッセイが幅広く利用されていることも、イムノアッセイ診断薬の需要を大きく伸ばしています。
慢性疾患と感染症の流行
慢性疾患や感染症の流行が世界のイムノアッセイ市場を牽引しています。これらの疾患の罹患率が伸び続ける中、さまざまな疾患の診断やモニタリングに向けたイムノアッセイに対する需要が高まっています。このため、革新的な製品が開発され、イムノアッセイをベースとしたポイントオブケア(POC)検査や迅速検査の採用が進んでいます。イムノアッセイは、水痘、デング熱、エボラ出血熱、インフルエンザ、肝炎などのさまざまな感染症の診断に用いられています。そして、臨床検体中の特定のウイルス、ウイルス抗原、抗体の存在を検出する貴重なツールです。医療従事者は、早期診断と疾患とその原因物質の正確な検出によって適切な治療を導くことによってのみ、この問題に効果的に対処することができます。
例えば、SARS-CoV-2感染時にはrRT-PCRが重要な役割を果たしましたが、今後のパンデミックではイムノアッセイがさらに必要になると予測されます。このような疾病負担の増大に伴い、イムノアッセイに対する需要も増加しており、世界のイムノアッセイ市場の成長を促進しています。
技術の進歩
ここ数年、バイオテクノロジー部門での技術の進歩が目覚ましく、イムノアッセイ市場でも技術革新が進んでいます。イムノアッセイの特異性を向上させる新たな技術や方法によって、これらの進歩は検査の特性や可能性を向上させ、最終的にはよりよい疾患の診断や治療につながることを目指しています。例えば、2022年にBiosensorsに掲載された「The advancement in nanotechnology and biotechnology(ナノテクノロジーとバイオテクノロジーの進歩)」と題された論文では、「ナノザイム(BD1)」として知られる固有の酵素のような特性を持つ新しいタイプのナノ材料の発明について述べられています。これらのナノザイムは異なる触媒機構を持ち、酵素を模倣し、検出感度と選択性を向上させるイムノアッセイを構築する際の標識として設計することができます。ナノザイムは、調整可能な高い触媒活性を示し、調製が容易で、安定性が高く、低コストです。これらの要因により、ナノザイムは天然酵素の欠点を解消することができるため、天然酵素よりも大きな支持を得ています。イムノアッセイの感度を向上させるこれらの進歩は、世界のイムノアッセイ市場の成長をさらに後押ししています。
当レポートでは、世界のイムノアッセイ市場について調査分析し、市場規模と予測、市場力学、主要企業情勢と見通しなどを提供しています。
Global immunoassay market is projected to witness a CAGR of 4.8% during the forecast period 2024-2031, growing from USD 34.11 billion in 2023 to USD 49.63 billion in 2031. Growth in the global immunoassay market is driven by various factors such as the rising prevalence of chronic diseases and infectious diseases, the growing elderly population, technological advancements and innovations in the biotech industry, increased healthcare expenditure, and government initiatives.
The global immunoassay market is undergoing robust growth due to the growing prevalence of chronic diseases around the world, such as cardiovascular diseases, diabetes, and cancer. A sedentary lifestyle, unhealthy diet, and increasing alcohol and tobacco consumption are the main risk factors that are contributing to the growing number of patients with chronic diseases. An increasing number of infectious diseases are also accelerating the growth of the global immunoassay market, as immunoassay has an important role in detecting and monitoring several diseases. Increase in elderly population is one of the most common risk factors for chronic as well as infectious diseases, as elderly people are more prone to these diseases. Immunoassay is an important tool for accurate and fast diagnosis of these diseases in terms of screening and regular monitoring. To deliver high-quality medical care and upgrade healthcare facilities, governments are encouraging private companies to invest more in research and development (R&D) of more effective and efficient immunoassay platforms and technologies. Moreover, wide applications of immunoassay in different healthcare sectors like hospitals, clinics, biotechnology companies are significantly increasing the demand for immunoassay diagnostics.
Increasing Prevalence of Chronic and Infectious Diseases
The increasing prevalence of chronic and infectious diseases drives the global immunoassay market. As the incidence of these diseases continues to rise, there is a growing demand for immunoassays to diagnose and monitor various conditions. This has led to the development of innovative products and the adoption of immunoassay-based point-of-care (POC) testing and rapid testing. Immunoassay is used to diagnose a variety of infectious diseases, including chickenpox, dengue, ebola, influenza, and hepatitis. It is a valuable tool for detecting the presence of specific viruses, viral antigens, or antibodies in clinical specimens. Healthcare professionals can only effectively address this issue by guiding the appropriate treatment through early diagnosis and accurate detection of the disease and its causing agent.
For instance, rRT-PCR played a crucial role during SARS-CoV-2 infection, and it is expected that immunoassay will further be required in future pandemics. With growing burden of these diseases, demand for immunoassay is also increasing, facilitating growth of global immunoassay market.
Technological Advancements
Over the past few years, there has been a surge of favorable technological advancements in the biotechnology sector, which, in turn, has also led to innovation in the immunoassay market. With novel techniques and methods to improve the immunoassay's specificity, these advancements aim to improve the characteristics and potential of the test, which may ultimately lead to better disease diagnosis and treatment. For instance, an article titled "The advancement in nanotechnology and biotechnology", published in Biosensors journals in the year 2022, described the invention of a new type of nanomaterial with intrinsic enzyme-like characteristics known as "nanozymes[BD1]". These nanozymes have different catalytic mechanisms, mimic enzymes, and can be designed as labels in constructing immunoassays to improve detection sensitivity and selectivity. Nanozymes exhibit high catalytic activity with tunability, easy preparation, high stability, and low cost. Due to these factors, nanozymes are gaining significant traction over natural enzymes, as they also eliminate the latter's defects. These advancements to improve immunoassays sensitivity further propel the growth of global immunoassay market.
Government Initiatives
Immunoassays are valuable tools used for various purpose such as disease diagnosis, research and development in biopharmaceuticals, including vaccines and gene and cell therapy, and drug monitoring. Due to its wide applications, governments around the globe have initiated several policies and programs, emphasizing the importance of technological advancements and improvements in immunoassay technique quality. Governments are investing billions of dollars in R&D to bring innovation in modern immunoassay diagnostic techniques.
For instance, in September 2023, the National Institute of Justice (NIJ) announced funding of $1.9 million to support forensic science research under its Public Labs R&E program. This funding helps NIJ to improve the examination and analysis of the most efficient, reliable, accurate, and cost-effective methods of analysis in the public forensic labs, including the development of a method for product and biological tissue analysis and assess cross-reactivity of immunoassay.
Increasing Volume of ELISA
Enzyme-linked immunosorbent assay (ELISA) is one of the most widely used immunoassay methods against HCoVs (Human Coronaviruses) and other viruses. Due to its ease of use with simple procedure, high throughput, rapid, high sensitivity, and good specificity, ELISA is gaining popularity among the major players. ELISA is a safe, eco-friendly, and cost-effective essay diagnostic procedure. Due to this, many major players are launching innovative techniques in ELISA to improve their product portfolios.
For instance, in October 2023, QIAGEN launched QuantiFERON-EBV RUO. This was designed to support research and development in EBV infection (Ebola Virus) and EBV-related malignancies. It uses QuantiFERON technology, along with ELISA detection system, to enable the researcher to study the immune response in the virus, which will further assist in improving the medical treatment against these viruses. These new launches and innovations in immunoassays are driving the global immunoassay market.
Growing Applications of Immunoassay
Immunoassay tests have a vast area of applications, including medical diagnostics, environmental testing, and food safety. Immunoassay tests are used for diagnosing infectious diseases, such as HIV, hepatitis, and tuberculosis, screening and monitoring for drugs abuse, and identifying and measuring allergens in food and environmental samples. They also gain traction as they provide rapid and accurate diagnostic results for point-of-care testing in different healthcare settings. Due to this, many market players are launching novel products in immunoassays to enhance their diagnostic products portfolio.
For instance, in May 2023, Beckman Coulter, a leader in clinical diagnostics, launched DxI 9000 Access Immunoassay Analyzer. This product has the potential to run up to 215 tests per hour. This technology has zero daily maintenance and will enable the healthcare professionals to improve throughput rates with great precision.
Future Market Scenario (2024-2031F)
Global immunoassay market is expected to grow tremendously in the coming years due to multiple factors. One of the primary drivers include an increasing prevalence of chronic and infectious diseases and a growing geriatric population. This will be further supported by rapid technological advancements and the integration of AI, resulting in accurate diagnosis and improved accuracy, especially for community-level surveillance. Moreover, government initiatives, policies, and programs are expected to enhance screening, which, in turn, will create a favorable market outlook. In line with this, increasing investments by public and private companies for research and development in their respective markets and collaborative ventures involving diagnostic device manufacturers and research institutions have spurred innovation leading to further growth of the global immunoassay market.
Key Players Landscape and Outlook
In the immunoassay industry, several public and private organizations are actively establishing strategic partnerships and distribution agreements to empower and strengthen each other's resources, gain insights regarding new markets and advanced technologies, and expand their businesses across the globe. Many big players are undergoing mergers and acquisitions, and partnerships to enhance and strengthen their product portfolios. For instance, on July 2023, Beckman Coulter Diagnostics, which is a leader in clinical diagnostics, and Fujirebio, a pioneer in neurological markers and a leader in manufacturing In Vitro Diagnostic (IVD), announced a new strategic partnership to combine their respective immunoassay strengths to support clinical trials, therapeutic development, reimbursement, and routine clinical adoption in neurodegenerative diseases.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work